- A four-year follow-up study of athletes with implantable cardioverter defibrillators (ICDs) found they suffered no irregular heartbeats, shock-related injuries or deaths while competing.
- ICD patients should talk to their doctors about their individual risks of participating in competitive sports.
Embargoed until 3 p.m. CT / 4 p.m. ET Monday, Monday, June 5, 2017
DALLAS, June 5, 2017 — A four-year study of athletes with implantable defibrillators confirms an earlier short-term study’s findings that competitive sports may be considered for many of these athletes, according to new research in the American Heart Association’s journal Circulation.
An implantable cardioverter defibrillator (ICD) is a battery-powered device placed under the skin that tracks the heart rate and delivers an electric shock when it detects a type of abnormal heart rhythm called an arrhythmia. In 2015, the American Heart Association issued a scientific statement advising that participating in competitive sports may be considered for athletes with ICDs, based on a 2013 study from a multinational registry of ICD patients which followed 372 athletes over a two-year period. The new study followed the same registry of athletes for a four-year period.
“Even though some people did receive shocks while they were participating in sports, no harm came to patients,” said Rachel Lampert, M.D., lead author of both studies and professor of internal medicine at Yale School of Medicine. “After a four-year follow-up, we still did not see any failures of the device to terminate an arrhythmia, or injuries related to the arrhythmia or device, in these patients.”
Researchers followed 440 ICD recipients, ages 10-60, for an average of nearly four years each. They included competitive athletes at the national and international level, high school and college athletes, and others who participated in vigorous sports such as running, basketball, soccer, tennis, volleyball, skiing and snowboarding.
One hundred twenty-one people received a total of 184 shocks during the study. Of the total study population:
- 7 percent received appropriate shocks while participating in competition or practice (identical to the 2013 study);
- 5 percent received shocks during other physical activities;
- 6 percent received shocks while resting.
According to Lampert, the current study’s longer follow-up period and larger number of participants enabled the researchers to identify one group of athletes for whom vigorous sports may be less safe: athletes who have a particular type of heart disease called arrhythmogenic right ventricular cardiomyopathy (ARVC), a rare inherited condition where muscle tissue in the right ventricle dies and is replaced with scar tissue, which disrupts the heart's electrical signals and causes arrhythmias.
“Patients with ARVC were more likely than others to experience life-threatening ventricular arrhythmias requiring shock during sports, and more likely to require multiple shocks to terminate their arrhythmias during physical activity,” Lampert said. “While all the shocks were ultimately successful in this study, this raises concern that vigorous physical activity could lead to arrhythmias that would not be terminated by the device. Although the ICD did work eventually and got the ARVC patients out of the arrhythmias, we don't like to see people requiring multiple shocks.”
Other athletes who have these devices and want to participate in sports should talk to their doctors, Lampert said, because the risk for many of them is lower than had been previously thought.
Co-authors are Brian Olshansky, M.D.; Hein Heidbuchel, M.D., Ph.D.; Christine Lawless, M.D.; Elizabeth Saarel, M.D.; Michael Ackerman, M.D.; Hugh Calkins, M.D.; N.A. Mark Estes, M.D.; Mark S. Link, M.D.; Barry J Maron, M.D.; Frank Marcus, M.D.; Melvin Scheinman, M.D.; Bruce L. Wilkoff, M.D.; Douglas P. Zipes, M.D.; Charles I. Berul, M.D.; Alan Cheng, M.D.; Luc Jordaens, M.D., Ph.D.; Ian Law, M.D.; Michele Loomis, A.P.R.N.; Rik Willems, M.D., Ph.D.; Cheryl Barth, B.S.; Karin Broos, B.A.; Cynthia Brandt, M.D.; James Dziura, Ph.D.; Fangyong Li, M.S.; Laura Simone, B.A.; Katleen Vandenberghe, Ph.D. and David Cannom, M.D.
Author disclosures are on the manuscript.
Boston Scientific Corporation, Medtronic Inc., and St. Jude Medical funded the study.
- After June 5, 2017, view the manuscript online.
- Implantable Cardioverter Defibrillator (ICD)
- Living With Your Implantable Cardioverter Defibrillator (ICD)
- Follow AHA/ASA news on Twitter @HeartNews
- For updates and new science from the Circulation journal follow @CircAHA
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at www.heart.org/corporatefunding.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies, and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
For Media Inquiries and AHA/ASA Spokesperson Perspective: (214) 706-1173
Darcy Spitz: (212) 878-5940; email@example.com
For Public Inquiries: (800)-AHA-USA1 (242-8721)
Life is why, science is how . . . we help people live longer, healthier lives.